Literature DB >> 19561839

Bendamustine (treanda) for chronic lymphocytic leukemia: a brief overview.

Hoyee Leong1, Mary Ellen Bonk.   

Abstract

Entities:  

Year:  2009        PMID： 19561839      PMCID： PMC2697069     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  18 in total

1.  The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.

Authors:  Stefan Knop; Christian Straka; Michael Haen; Renate Schwedes; Holger Hebart; Hermann Einsele
Journal:  Haematologica       Date:  2005-09       Impact factor: 9.941

2.  Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.

Authors:  T Lissitchkov; G Arnaudov; D Peytchev; Kh Merkle
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-15       Impact factor: 4.553

3.  Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.

Authors:  Manuela A Bergmann; Maria E Goebeler; Michael Herold; Bertold Emmerich; Martin Wilhelm; Corinna Ruelfs; Lothar Boening; Michael J Hallek
Journal:  Haematologica       Date:  2005-10       Impact factor: 9.941

4.  Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.

Authors:  Alexander Schmittel; Maren Knödler; Patricia Hortig; Karsten Schulze; Eckhard Thiel; Ulrich Keilholz
Journal:  Lung Cancer       Date:  2006-11-13       Impact factor: 5.705

5.  Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study.

Authors:  Hubert Köppler; Jochen Heymanns; Annette Pandorf; Rudolf Weide
Journal:  Leuk Lymphoma       Date:  2004-05

6.  Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).

Authors:  Michael Koenigsmann; Wolfgang Knauf; Michael Herold; Rita Pasold; Gerd Müller; Henning Eschenburg; Christoph Kahl; Volker Lakner; Michael Assmann; Kathleen Jentsch-Ullrich; Martin Mohren; Rainer Bartsch; Astrid Franke
Journal:  Leuk Lymphoma       Date:  2004-09

7.  Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).

Authors:  Wolf Köster; G Stamatis; A Heider; K Avramidis; H Wilke; J A Koch; M Stahl
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

8.  Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

Authors:  Wolfram Pönisch; Marta Rozanski; Hartmut Goldschmidt; Franz Albert Hoffmann; Thomas Boldt; Andreas Schwarzer; Ute Ritter; Robert Rohrberg; Elke Schwalbe; Jens Uhlig; Thomas Zehrfeld; Veronika Schirmer; Antje Haas; Ute Kreibich; Dietger Niederwieser
Journal:  Br J Haematol       Date:  2008-08-24       Impact factor: 6.998

9.  A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.

Authors:  Marika Rasschaert; Dirk Schrijvers; Jan Van den Brande; Joke Dyck; Johan Bosmans; Karlheinz Merkle; Jan B Vermorken
Journal:  Anticancer Drugs       Date:  2007-06       Impact factor: 2.248

10.  Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Authors:  Jonathan W Friedberg; Philip Cohen; Ling Chen; K Sue Robinson; Andres Forero-Torres; Ann S La Casce; Luis E Fayad; Alberto Bessudo; Elber S Camacho; Michael E Williams; Richard H van der Jagt; Jennifer W Oliver; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544
View more
  2 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  Massive scalp myiasis with bleeding in a patient with multiple malignancies.

Authors:  Uwe Wollina
Journal:  Int Wound J       Date:  2010-05-28       Impact factor: 3.315
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.